Evidence map›Paper›PMID 26444095›Full record

Trial reportJournal of Parkinson's disease2015

Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects.

David K Simon, Tanya Simuni, Jordan Elm, Joanne Clark-Matott, Allison K Graebner, Liana Baker, Susan R Dunlop, Marina Emborg, Cornelia Kamp, John C Morgan and 4 more

Open access · greenAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of Parkinson's disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

David K SimonNeurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Tanya SimuniNeurology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
Jordan ElmBiostatistics, Medical University of South Carolina, Charleston, SC, USA.
Joanne Clark-MatottNeurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Allison K GraebnerNeurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Liana BakerClinical Trials Coordination Center, University of Rochester, Medical Center, Rochester, NY, USA.
Susan R DunlopNeurology, Johns Hopkins University, Baltimore, MD, USA.
Marina EmborgWisconsin National Primate Research Center and Department of Medical Physics, University of Wisconsin, Madison, WI, USA.
Cornelia KampClinical Materials Services Unit, University of Rochester, Medical Center, Rochester, NY, USA.
John C MorganNeurology, Medical College of Georgia, Augusta, GA, USA.
G Webster RossNeurology, Veterans Affairs Pacific Islands Health Care System, Honolulu, HI, USA.
Saloni SharmaClinical Trials Coordination Center, University of Rochester, Medical Center, Rochester, NY, USA.
Bernard RavinaVoyager Therapeutics, Inc., Cambridge, MA, USA.
NINDS NET-PD Investigators
Beth Israel Deaconess Medical Center · USAugusta University · USNorthwestern University · USUniversity of Wisconsin–Madison · USGTx (United States) · USJohns Hopkins University · USUniversity of Rochester Medical Center · USVoyager Therapeutics (United States) · US

Funding

WNPRC Supplemental Request for Nonhuman Primate Enclosures to Equip HIV/AIDS-Related Research FacilitiesP51OD011106 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI Dorota A. Grejner-Brzezinska · 2012 to 2026
$150.7M
Supplemental Funding to the NET PD StudiesU01NS043128 · NINDS · UNIVERSITY OF ROCHESTER · PI KIEBURTZ, KARL D. · 2001 to 2014
$24.2M
Parkinson's Disease Clinical Trial: Statistical CenterU01NS043127 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LUO, SHENG · 2001 to 2015
$8.0M
Parkinson Disease Neuroprotection Clinical TrialU10NS044482 · NINDS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI SIMON, DAVID K. · 2002 to 2013
$955k
NIH HHS P51 OD011106NINDS NIH HHS U01 NS043128NINDS NIH HHS U10 NS044482
6 · The paper itself

Abstract

Pioglitazone, an oral hypoglycemic agent, recently failed to show promise as a disease-modifying agent in a 44-week phase 2 placebo-controlled study in 210 Parkinson's disease (PD) subjects. We analyzed peripheral biomarkers, including leukocyte PGC-1α and target gene expression, plasma interleukin 6 (IL-6) as a marker of inflammation, and urine 8-hydroxydeoxyguanosine (8OHdG) as a marker of oxidative DNA damage. Baseline or changes from baseline in biomarker levels were not associated with the rate of progression of PD. Pioglitazone did not significantly alter biomarker levels. Other agents that more effectively target these mechanisms remain of potential interest as disease modifying therapies in PD.

Indexed as

Disease ProgressionParkinson Disease8-Hydroxy-2'-DeoxyguanosineAgedBiomarkersDeoxyguanosineFemaleGene ExpressionHumansHypoglycemic AgentsInflammationInterleukin-6MaleMiddle AgedOxidative StressPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha8-Hydroxy-2'-DeoxyguanosineBiomarkersDeoxyguanosineHypoglycemic AgentsIL6 protein, humanInterleukin-6Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPioglitazonePPARGC1A protein, humanThiazolidinedionesTranscription Factors8-hydroxydeoxyguano sine8OHdGbiomarkercytokineIL-6inflammationinterleukin-6oxidative stressParkinson’s diseasePGC-1alphapioglitazone

Identifiers

PMID26444095
PMCPMC5061495
OpenAlexW2170205373

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.